Home Newsfeeds Telsey Advisory Group Reiterates Outperform on Dollar Gen, Maintains $242 Price Target

Telsey Advisory Group Reiterates Outperform on Dollar Gen, Maintains $242 Price Target

Telsey Advisory Group analyst Joseph Feldman reiterates Dollar Gen (NYSE:DG) with a Outperform and maintains $242 price target.

byBenzinga Newsdesk

March 17, 2023

1 minute read

Telsey Advisory Group analyst Joseph Feldman reiterates Dollar Gen (NYSE:DG) with a Outperform and maintains $242 price target.

Stock Futures Dive After Fitch US Downgrade: Why This Analyst Forecasts ‘Pretty Painful’ And ‘Tricky’ August

By Shanthi Rexaline

August 2, 7:43 AM

Fitch's downgrade could set forth economic fears that has so far remained an undercurrent and impede the recent market momentum.

AMD

Reported Late Thursday March 16, Hallador Energy Company Reports FFY22 Financial And Operating Results; FY22 Net Income Of $18.1M, $0.57/Share

By Happy Mohamed

March 17, 1:28 AM

Hallador Energy Company (NASDAQ – HNRG) today reported net income of $18.1 million, $0.57 per share for the full year 2022. Brent Bilsland, President and Chief Executive

HNRG

News
Tech

Elon Musk Reacts As Apple Offers Opt-Out Option For OpenAI’s ChatGPT Integration, Easing Privacy Concerns

By Rounak Jain

June 12, 6:37 AM

Apple Inc.'s Craig Federighi has revealed that users will be able to opt out of the integration of OpenAI's ChatGPT.

AAPL

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $40

By Benzinga Newsdesk

November 7, 10:00 AM

Morgan Stanley analyst Matthew Harrison maintains Akero Therapeutics (NASDAQ:AKRO) with a Equal-Weight and raises the price target from $30 to $40.

AKRO

Telsey Advisory Group Reiterates Outperform on Dollar Gen, Maintains $242 Price Target

Related Posts

Stock Futures Dive After Fitch US Downgrade: Why This Analyst Forecasts ‘Pretty Painful’ And ‘Tricky’ August

Reported Late Thursday March 16, Hallador Energy Company Reports FFY22 Financial And Operating Results; FY22 Net Income Of $18.1M, $0.57/Share

Elon Musk Reacts As Apple Offers Opt-Out Option For OpenAI’s ChatGPT Integration, Easing Privacy Concerns

Morgan Stanley Maintains Equal-Weight on Akero Therapeutics, Raises Price Target to $40